Abstract
Heart failure is a leading cause of morbidity and mortality; yet gene regulatory mechanisms driving cell type-specific pathologic responses remain undefined. Here, we present the cell type-resolved transcriptomes, chromatin accessibility, histone modifications and chromatin organization of 36 non-failing and failing human hearts profiled from 776,479 cells spanning all cardiac chambers. Integrative analyses revealed dynamic changes in cell type composition, gene regulatory programs and chromatin organization, which expanded the annotation of cardiac cis-regulatory sequences by ten-fold and mapped cell type-specific enhancer-gene interactions. Cardiomyocytes and fibroblasts particularly exhibited complex disease-associated cellular states, gene regulatory programs and global chromatin reorganization. Mapping genetic association data onto cell type-specific regulatory programs revealed likely causal genetic contributors to heart failure. Together, these findings provide comprehensive, multimodal gene regulatory maps of the human heart in health and disease, offering a valuable framework for designing precise cell type-targeted therapies for treating heart failure.
Competing Interest Statement
The following authors declare competing interests. Consultancy fees: SGD (Abbott), KJG (Genentech). KJG has received honoraria from Pfizer, holds stock in Neurocrine Biosciences, and his spouse is employed at Altos Labs. SGD acknowledges research support from Novartis. RME is an employee and shareholder of Pfizer. BR is a shareholder and consultant of Arima Genomics Inc. and cofounder of Epigenome Technologies, Inc. All other authors declare no competing interests.
Funding Statement
This project was supported by: Foundation of NIH (KJG, BR, NCC, SGD) AHA Heart Failure Strategically Focused Research Network, 16SFRN29020000 (SGD) NIH NHLBI R01 HL135121 (SGD) NIH NHLBI 1R01HL166513 (SGD) Merit Review Award I01 CX002291 (SGD) U.S. Department of Veterans Affairs (SGD) Nora Eccles Treadwell Foundation (SGD) NIH HG012059 (KJG) NIH NHLBI T32HL007444 (ENF, ARH) NIH-1K08HL168315-01 (ET) Life Sciences Research Foundation (ZW)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of the Utah Transplantation Affiliated Hospitals Cardiac Transplant Program (i.e., University of Utah Health Science Center, Intermountain Medical Center, and the Veterans Administration Salt Lake City Health Care System) gave ethical approval for this work (IRB 00030622).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
